

Product datasheet for TL312856V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

GAD65 (GAD2) Human shRNA Lentiviral Particle (Locus ID 2572)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: GAD65 (GAD2) Human shRNA Lentiviral Particle (Locus ID 2572)

Locus ID: 2572 Synonyms: GAD65

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: GAD2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 000818, NM 001134366, NM 000818.1, NM 000818.2, NM 001134366.1, BC126327,

BC029517, BC039038, BC047899, BC126329, NM 001134366.2

UniProt ID: Q05329

Summary: This gene encodes one of several forms of glutamic acid decarboxylase, identified as a major

autoantigen in insulin-dependent diabetes. The enzyme encoded is responsible for catalyzing the production of gamma-aminobutyric acid from L-glutamic acid. A pathogenic role for this

enzyme has been identified in the human pancreas since it has been identified as an

autoantibody and an autoreactive T cell target in insulin-dependent diabetes. This gene may also play a role in the stiff man syndrome. Alternative splicing results in multiple transcript

variants that encode the same protein. [provided by RefSeq, Oct 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).